Insider transaction details
Whitehawk Therapeutics (NASDAQ: WHWK) Chief Executive Officer David James Lennon sold 26,858 shares of the company's common stock on April 2, 2026, at a price of $3.48 per share, for an aggregate value of $93,465. The transaction was disclosed in a Form 4 filing with the U.S. Securities and Exchange Commission and is reported as a broker-assisted sale intended to cover tax obligations arising from the vesting of restricted stock units.
The company's share price was trading at $3.51 at the time of the filing, a level close to the price at which the CEO's shares were sold.
Related option activity
On April 1, 2026, Lennon executed option exercises on 775,828 shares of common stock and acquired 831,148 shares through a stock option award. The exercised options carry an exercise price of $3.54 and have an expiration date of April 1, 2036, according to the filing.
Share performance context
Whitehawk's shares have risen 114% over the last 12 months, reflecting notable price movement for the company over that period.
Clinical and regulatory developments
Separately from the insider activity, Whitehawk Therapeutics announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for HWK-007, a PTK7-targeted antibody-drug conjugate. The company has initiated patient recruitment for a Phase 1 clinical trial of HWK-007, which will initially evaluate the drug's activity in lung, ovarian, and endometrial cancers.
According to Whitehawk, PTK7 is present in approximately 70% of tumors, a detail the company highlighted when discussing the potential relevance of HWK-007 to its oncology pipeline. The firm characterized these steps as important progress in advancing its cancer drug development efforts.
Takeaway
The insider sale was disclosed as part of standard filings and was executed to satisfy tax liabilities tied to vested equity. At the same time, the company is progressing its clinical program for HWK-007 following FDA IND clearance and the start of Phase 1 enrollment.